Review of guidelines for bone mineral density testing and treatment of osteoporosis.

被引:37
|
作者
Lewiecki E.M. [1 ]
机构
[1] Osteoporosis Center, 300 Oak St. NE, Albuquerque, 87106, NM
关键词
Bone Mineral Density; Osteoporosis; Bone Mineral Density Testing; National Osteoporosis Foundation; United States Preventive Service Task Force;
D O I
10.1007/s11914-005-0014-x
中图分类号
学科分类号
摘要
Clinical practice guidelines (CPGs) are systematically developed statements intended to influence the behavior of health care providers and improve patient care. There are many CPGs with recommendations for selection of patients for bone mineral density testing and pharmacologic treatment of osteoporosis. Health care provider adherence rates for these CPGs are low. The multiplicity of osteoporosis CPGs directed to the same health care providers may play a role in their limited utilization in clinical practice. Similarities, differences, and conflicts in osteoporosis CPGs with wide distribution in the United States were examined. The analysis showed similarities as well as substantial variation in the patient populations addressed, inconsistency of some recommendations, differences in clinical risk factors identified, and sometimes limitations in clinical applications. If the number and diversity of osteoporosis CPGs is adversely affecting their use in clinical practice, then collaboration of stakeholder organizations to develop more consistent CPGs, in combination with systems-based approaches for their implementation, may improve patient care and reduce the burden of osteoporotic fractures.
引用
收藏
页码:75 / 83
页数:8
相关论文
共 50 条
  • [1] Effects of bone density testing at health fairs on awareness and treatment of osteoporosis.
    Boyd, JL
    Holcomb, JP
    Rothenberg, RJ
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S171 - S171
  • [2] Bone mineral density: testing for osteoporosis
    Sheu, Angela
    Diamond, Terry
    AUSTRALIAN PRESCRIBER, 2016, 39 (02) : 35 - 39
  • [3] Initiation of Osteoporosis Treatment after Bone Mineral Density Testing
    A. Pressman
    B. Forsyth
    B. Ettinger
    A. N. A. Tosteson
    Osteoporosis International, 2001, 12 : 337 - 342
  • [4] Initiation of osteoporosis treatment after bone mineral density testing
    Pressman, A
    Forsyth, B
    Ettinger, B
    Tosteson, ANA
    OSTEOPOROSIS INTERNATIONAL, 2001, 12 (05) : 337 - 342
  • [5] Octreotide increases bone mineral density in a patient with carcinoid and osteoporosis.
    McCommon, D
    Tauer, K
    Palmieri, GM
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S380 - S380
  • [6] Alendonate improved bone mineral density in patients with juvenile osteoporosis.
    Madyastha, P
    Ries, W
    Hollis, B
    Reed, F
    Key, L
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S400 - S400
  • [7] Alendronate increases bone mineral density in male idiopathic osteoporosis.
    Weber, TJ
    Drezner, MK
    JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 : S278 - S278
  • [8] High heritability of bone mineral density in pedigrees of men with idiopathic osteoporosis.
    Van Pottelbergh, I
    Wang, C
    Cohen-Solal, M
    Martinez, M
    Ostertag, A
    Kaufman, J
    de Vernejoul, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S129 - S129
  • [9] Effect of raloxifene on bone mineral density and bone markers in Japanese postmenopausal women with osteoporosis.
    Morii, H
    Taketani, Y
    Ohashi, Y
    Nakamura, T
    Fukunaga, M
    Itabashi, A
    Sarkar, S
    Harper, KD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S273 - S273
  • [10] Review of guidelines for testing and treatment of osteoporosis
    Piet P. M. M. Geusens
    Current Osteoporosis Reports, 2003, 1 (2) : 59 - 65